2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of TMDX based on the data provided:

**Simple Numbers & Basic Analysis:**

*   **Current Price:** $122.69
*   **5-day SMA:** $122.70
*   **20-day SMA:** $127.45
*   **60-day SMA:** $126.30
*   **RSI:** 40.99
*   **PPO:** -0.64
*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommended)

**1) Return Rate vs. S&P 500 (VOO):**

*   **Company Overview:** Transmedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care systems for transplantation therapy.
*   **TMDX Cumulative Return:** 199.45%
*   **VOO Cumulative Return:** 70.76%
*   **Divergence:**
    *   **Current:** 128.7
    *   **Relative Divergence:** 62.2 (This means the current divergence is in the 62.2nd percentile of its historical range).

*   **Alpha, Beta Analysis:**

    | Year       | CAGR    | MDD    | Alpha   | Beta   | Cap(B) |
    |------------|---------|--------|---------|--------|--------|
    | 2020-2022  | 94.0%   | 60.2%  | 96.0%   | 1.3    | 2.1    |
    | 2021-2023  | 65.0%   | 60.2%  | 64.0%   | 1.7    | 2.7    |
    | 2022-2024  | 130.0%  | 51.7%  | 111.0%  | 1.8    | 2.1    |
    | 2023-2025  | 120.0%  | 53.4%  | 58.0%   | 1.4    | 4.2    |

**Analysis of Return Rate:**

*   TMDX has significantly outperformed the S&P 500, with a much higher cumulative return. The divergence of 128.7 indicates a substantial performance gap.
*   The relative divergence of 62.2 suggests that, while TMDX is currently outperforming, its divergence isn't at its absolute historical peak.
*   **CAGR:** The Compound Annual Growth Rate (CAGR) has been very high in all reported periods.
*   **MDD:** The Maximum Drawdown (MDD) indicates the largest peak-to-trough decline during the period, suggesting a degree of volatility.
*   **Alpha:** The Alpha is very high, indicating the portfolio has performed well relative to the benchmark index (S&P500).
*   **Beta:** The Beta is consistently above 1, meaning the stock is more volatile than the S&P 500.
*   **Cap(B):** Market capitalization in Billions, consistently growing over the analyzed period.

**2) Recent Stock Price Fluctuations:**

*   **Close Price:** $122.69
*   **Last Market Change:** Up $0.85 from the previous close.
*   The 5-day SMA is slightly above the current price, while the 20-day and 60-day SMAs are higher, suggesting a potential short-term downward trend, or at least a recent consolidation.

**3) RSI, PPO, and Expected Return:**

*   **RSI:** 40.99 indicates the stock is not overbought or oversold.
*   **PPO:** -0.64 suggests that the short-term moving average is below the long-term moving average, indicating a possible downtrend.
*   **Market Risk Indicator (MRI):** 0.8 suggests a medium investment risk, supporting investment.
*   **Hybrid Signal:** Suggests a "Buy" strategy with 100% cash allocation (potentially converting to 7 shares), which is considered "Very Safe" with an MRI of 0.9. It recommends a small monthly investment.
*   **Recent Divergence Change:** -3.1 indicates a short-term price decrease.
*   **Expected Return:** 56.4% is a high expected excess return compared to the S&P 500 over a long-term investment (2+ years).

**4) Recent News & Significant Events:**

*   **Mixed News:** The news headlines present a mixed picture.
    *   One article highlights "Trading the Move, Not the Narrative," suggesting short-term trading opportunities.
    *   Another notes a stock fall *despite* positive earnings, indicating market sentiment isn't always aligned with financial results.
    *   Several articles discuss insider sales or institutional selling (Eventide), which *can* be a negative signal (but not always).
    *   However, articles also mention reasons to retain the stock and highlight it as an under-the-radar performer.

**4-2) Analyst Opinions:**

*   **Consensus:** A "Buy" rating (Mean of 1.67) with 11 opinions suggests overall positive sentiment from analysts.
*   **Target Price:** The average target price ($144.73) is significantly above the current price, suggesting potential upside.
*   **Recent Rating Changes:** Absence of specific changes makes it difficult to assess recent trends in analyst sentiment.

**5) Comprehensive Analysis:**

TMDX is a high-growth, high-volatility stock that has significantly outperformed the S&P 500. The strong CAGR, Alpha, and Beta figures confirm this. The high expected return further strengthens the investment rationale.

**Mixed Signals:**

*   **Technical Indicators:** The recent price action, combined with the RSI and PPO, suggests a potential short-term downtrend or consolidation phase. This contradicts the overall bullish outlook based on fundamental performance.
*   **News:** The news headlines are mixed, with some potential negative signals like insider/institutional selling offsetting positive earnings reports and analyst recommendations.

**Conclusion & Recommendation:**

*   TMDX presents a potentially attractive investment opportunity due to its strong historical performance and high expected returns.
*   However, the high volatility (Beta) and recent mixed signals suggest that investors should exercise caution.
*   The "Very Safe" Hybrid Signal indicates a low entry risk for long-term investments, with small monthly investments.
*   **Recommendation:** A buy-and-hold strategy could be beneficial, but investors should carefully monitor news, technical indicators, and analyst ratings. Consider dollar-cost averaging to mitigate the risk of short-term price fluctuations. A smaller initial allocation, following the hybrid signal, is recommended to minimize risk.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.